Literature DB >> 18815274

Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Min Dong1, Huisheng Liu, William H Tepp, Eric A Johnson, Roger Janz, Edwin R Chapman.   

Abstract

Botulinum neurotoxin E (BoNT/E) can cause paralysis in humans and animals by blocking neurotransmitter release from presynaptic nerve terminals. How this toxin targets and enters neurons is not known. Here we identified two isoforms of the synaptic vesicle protein SV2, SV2A and SV2B, as the protein receptors for BoNT/E. BoNT/E failed to enter neurons cultured from SV2A/B knockout mice; entry was restored by expressing SV2A or SV2B, but not SV2C. Mice lacking SV2B displayed reduced sensitivity to BoNT/E. The fourth luminal domain of SV2A or SV2B alone, expressed in chimeric receptors by replacing the extracellular domain of the low-density lipoprotein receptor, can restore the binding and entry of BoNT/E into neurons lacking SV2A/B. Furthermore, we found disruption of a N-glycosylation site (N573Q) within the fourth luminal domain of SV2A rendered the mutant unable to mediate the entry of BoNT/E and also reduced the entry of BoNT/A. Finally, we demonstrate that BoNT/E failed to bind and enter ganglioside-deficient neurons; entry was rescued by loading exogenous gangliosides into neuronal membranes. Together, the data reported here demonstrate that glycosylated SV2A and SV2B act in conjunction with gangliosides to mediate the entry of BoNT/E into neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815274      PMCID: PMC2592654          DOI: 10.1091/mbc.e08-07-0765

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  59 in total

1.  Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.

Authors:  Lilia K Koriazova; Mauricio Montal
Journal:  Nat Struct Biol       Date:  2003-01

Review 2.  Identification of the major steps in botulinum toxin action.

Authors:  Lance L Simpson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

Review 3.  Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.

Authors:  David Dodick; Andrew Blumenfeld; Stephen D Silberstein
Journal:  Clin Dermatol       Date:  2004 Jan-Feb       Impact factor: 3.541

Review 4.  Botulinum toxin as a biological weapon: medical and public health management.

Authors:  S S Arnon; R Schechter; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; J Hauer; M Layton; S Lillibridge; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; D L Swerdlow; K Tonat
Journal:  JAMA       Date:  2001-02-28       Impact factor: 56.272

Review 5.  Implications of the SNARE hypothesis for intracellular membrane topology and dynamics.

Authors:  J E Rothman; G Warren
Journal:  Curr Biol       Date:  1994-03-01       Impact factor: 10.834

6.  The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction.

Authors:  Andreas Rummel; Stefan Mahrhold; Hans Bigalke; Thomas Binz
Journal:  Mol Microbiol       Date:  2004-02       Impact factor: 3.501

7.  Uptake of botulinum neurotoxin into cultured neurons.

Authors:  James E Keller; Fang Cai; Elaine A Neale
Journal:  Biochemistry       Date:  2004-01-20       Impact factor: 3.162

8.  Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G.

Authors:  Andreas Rummel; Tino Karnath; Tina Henke; Hans Bigalke; Thomas Binz
Journal:  J Biol Chem       Date:  2004-04-30       Impact factor: 5.157

9.  Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I.

Authors:  Brian C Yowler; Richard D Kensinger; Cara-Lynne Schengrund
Journal:  J Biol Chem       Date:  2002-06-27       Impact factor: 5.157

10.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.

Authors:  Min Dong; David A Richards; Michael C Goodnough; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  J Cell Biol       Date:  2003-09-22       Impact factor: 10.539

View more
  95 in total

1.  Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.

Authors:  Abby R Kroken; Andrew P-A Karalewitz; Zhuji Fu; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

2.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  Expression and purification of neurotoxin-associated protein HA-33/A from Clostridium botulinum and evaluation of its antigenicity.

Authors:  Ali Sayadmanesh; Firouz Ebrahimi; Abbas Hajizade; Mosayeb Rostamian; Hani Keshavarz
Journal:  Iran Biomed J       Date:  2013

Review 4.  Infection, Pain, and Itch.

Authors:  Isaac M Chiu
Journal:  Neurosci Bull       Date:  2017-01-31       Impact factor: 5.203

5.  Bimodal modulation of the botulinum neurotoxin protein-conducting channel.

Authors:  Audrey Fischer; Yuya Nakai; Lisa M Eubanks; Colin M Clancy; William H Tepp; Sabine Pellett; Tobin J Dickerson; Eric A Johnson; Kim D Janda; Mauricio Montal
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

6.  Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Authors:  Jasmin Strotmeier; Stefan Mahrhold; Nadja Krez; Constantin Janzen; Jianlong Lou; James D Marks; Thomas Binz; Andreas Rummel
Journal:  FEBS Lett       Date:  2014-02-25       Impact factor: 4.124

7.  Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

Authors:  V Daniels; M Wood; K Leclercq; R M Kaminski; M Gillard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

8.  Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D.

Authors:  Yanfeng Zhang; Anna S Gardberg; Thomas E Edwards; Banumathi Sankaran; Howard Robinson; Susan M Varnum; Garry W Buchko
Journal:  Biochimie       Date:  2013-03-21       Impact factor: 4.079

Review 9.  Interaction of botulinum toxin with the epithelial barrier.

Authors:  Yukako Fujinaga
Journal:  J Biomed Biotechnol       Date:  2010-02-14

10.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.